Business Context and Reporting Period
This Form 8-K, filed on June 14, 2019, reports events occurring on June 13, 2019, involving Histogenics Corporation (the "Company") and Ocugen, Inc. The filing details amendments to a previously announced Merger Agreement and the execution of a Pre-Merger Financing agreement. The transaction involves the merger of Ocugen into Histogenics, with Ocugen shareholders expected to own approximately 83% of the combined entity and Histogenics shareholders approximately 17%.
Key Financial Metrics and Transaction Terms
- Pre-Merger Financing: Ocugen and Histogenics entered into a Securities Purchase Agreement with institutional investors for an aggregate purchase price of approximately $25.0 million, subject to a setoff of approximately $2.4 million for outstanding senior secured notes.
- Securities Issued: Ocugen agreed to sell 4,574,272 shares of common stock ("Initial Shares") and deposit an equal number into escrow ("Additional Shares") contingent on post-closing trading prices. Histogenics agreed to issue Series A, Series B, and Series C warrants.
- Merger Consideration: The Exchange Ratio was amended to 28.7650. Ocugen agreed to make milestone payments to Histogenics totaling $900,000 (subject to conditions), with payments scheduled from June 13, 2019, through September 30, 2019.
- Debt and Liquidity: The filing references approximately $2.4 million in senior secured notes previously issued by Ocugen to certain investors. The filing does not provide specific current cash balances or total debt figures for either entity outside of the transaction context.
Material Changes Versus Prior Period
The filing represents a material change to the April 5, 2019, Merger Agreement through Consent and Amendment No. 1. Key changes include:
- Exchange Ratio: Amended and restated to 28.7650.
- End Date: The deadline to consummate the merger was extended from July 31, 2019, to September 30, 2019.
- Conditions: Added a condition requiring the closing of an Asset Purchase Agreement between Histogenics and Medavate Corp. dated May 8, 2019.
- Restrictions: Added covenants restricting the issuance of securities by both parties until the Effective Time of the merger.
- Financing Structure: Introduced a complex warrant structure (Series A, B, and C) and escrow arrangements not present in the original agreement.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The transaction is contingent upon stockholder approvals, Nasdaq approvals, and the satisfaction of conditions in the Merger Agreement. A reverse stock split of Histogenics common stock is contemplated to ensure a volume-weighted average price of at least $10.00 per share prior to closing.
Risks and Contingencies:
- Termination Rights: Histogenics may terminate the agreement if Ocugen fails to make scheduled payments. The financing agreement may be terminated if closing does not occur by September 30, 2019.
- Penalty Provisions: Significant penalties apply for failure to deliver shares or maintain registration statements, including daily payments of 2.0% of the market value of undelivered shares or the purchase price.
- Forward-Looking Risks: Risks include failure to obtain regulatory or stockholder approvals, delays in clinical trials for Ocugen's product candidates, inability to raise additional capital, and potential dilution from the financing.
- Lock-Up Agreements: Officers, directors, and significant shareholders are subject to lock-up agreements restricting sales for 30 days after the "Trigger Date" (related to registration effectiveness or Rule 144 availability).
Important Facts for Investor Verification
- Verify the status of the Asset Purchase Agreement with Medavate Corp., which is now a condition precedent to the merger.
- Confirm the timing and effectiveness of the Form S-4 registration statement, which was amended to be filed by June 17, 2019.
- Monitor the volume-weighted average trading price of Histogenics stock to ensure it meets the $10.00 threshold required for the reverse stock split and financing closing.
- Review the specific terms of the Series A, B, and C warrants, particularly the reset provisions and blocker provisions limiting beneficial ownership to 4.99% or 9.99%.
- Assess the financial impact of the $2.4 million setoff against the $25.0 million financing proceeds and the scheduled $900,000 in milestone payments.